Cutaneous iontophoresis of vasoactive medications in patients with scleroderma‐associated pulmonary arterial hypertension

It remains unknown whether the cutaneous microvascular responses are different between patients with scleroderma‐associated pulmonary arterial hypertension (SSc‐PAH) and SSc without pulmonary hypertension (PH).

[1]  A. Tonelli,et al.  Management of Pulmonary Arterial Hypertension in Patients with Systemic Sclerosis , 2020, Integrated blood pressure control.

[2]  A. Hausladen,et al.  A pilot study on the kinetics of metabolites and microvascular cutaneous effects of nitric oxide inhalation in healthy volunteers , 2019, PloS one.

[3]  V. A. de Jesus Perez,et al.  The 6th World Symposium on Pulmonary Hypertension: what’s old is new , 2019, F1000Research.

[4]  A. Tonelli,et al.  Microvascular involvement in systemic sclerosis and systemic lupus erythematosus , 2019, Microcirculation.

[5]  Z. Jing,et al.  Risk stratification and medical therapy of pulmonary arterial hypertension , 2019, European Respiratory Journal.

[6]  Max L. Balter,et al.  The growing role of precision and personalized medicine for cancer treatment , 2018, Technology.

[7]  M. Humbert,et al.  Pulmonary hypertension in systemic sclerosis: different phenotypes , 2017, European Respiratory Review.

[8]  M. Roustit,et al.  Targeting the Prostacyclin Pathway: Beyond Pulmonary Arterial Hypertension. , 2017, Trends in pharmacological sciences.

[9]  R. Dweik,et al.  Novel Methods in Pulmonary Hypertension Phenotyping in the Age of Precision Medicine (2015 Grover Conference Series) , 2016, Pulmonary circulation.

[10]  R. Dweik,et al.  What is the best approach to a high systolic pulmonary artery pressure on echocardiography? , 2016, Cleveland Clinic Journal of Medicine.

[11]  A. Della Rossa,et al.  Post-occlusive reactive hyperaemia (POHR) in systemic sclerosis: very early disease (VEDOSS) represents a separate entity compared to established disease , 2016, Scandinavian journal of rheumatology.

[12]  R. Dweik,et al.  Treprostinil Iontophoresis in Idiopathic Pulmonary Arterial Hypertension. , 2015, American journal of respiratory and critical care medicine.

[13]  R. Dweik,et al.  Are Transcutaneous Oxygen and Carbon Dioxide Determinations of Value in Pulmonary Arterial Hypertension? , 2015, Microcirculation.

[14]  J. Mitchell,et al.  Role of prostacyclin in pulmonary hypertension , 2014, Global cardiology science & practice.

[15]  F. Maltais,et al.  Impaired angiogenesis and peripheral muscle microcirculation loss contribute to exercise intolerance in pulmonary arterial hypertension. , 2014, American journal of respiratory and critical care medicine.

[16]  R. Dweik,et al.  Sublingual microcirculation in pulmonary arterial hypertension. , 2014, Annals of the American Thoracic Society.

[17]  H. Heinzl,et al.  Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study , 2013, Annals of the rheumatic diseases.

[18]  J. Ioannidis,et al.  Geometry of the randomized evidence for treatments of pulmonary hypertension. , 2013, Cardiovascular therapeutics.

[19]  A. Jordão,et al.  Oxidative-Stress Biomarkers in Patients with Pulmonary Hypertension , 2013, Pulmonary circulation.

[20]  Oliver Distler,et al.  2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative. , 2013, Arthritis and rheumatism.

[21]  F. Dinenno,et al.  Reactive Hyperemia Occurs Via Activation of Inwardly Rectifying Potassium Channels and Na+/K+-ATPase in Humans , 2013, Circulation research.

[22]  M. Gladwin,et al.  Nitric oxide deficiency and endothelial dysfunction in pulmonary arterial hypertension. , 2013, American journal of respiratory and critical care medicine.

[23]  M. Roustit,et al.  Anodal Iontophoresis of a Soluble Guanylate Cyclase Stimulator Induces a Sustained Increase in Skin Blood Flow in Rats , 2013, The Journal of Pharmacology and Experimental Therapeutics.

[24]  C. Vizza,et al.  Systemic sclerosis patients with and without pulmonary arterial hypertension: a nailfold capillaroscopy study. , 2013, Rheumatology.

[25]  R. Dweik,et al.  Causes and circumstances of death in pulmonary arterial hypertension. , 2013, American journal of respiratory and critical care medicine.

[26]  C. Millet,et al.  Cathodal Iontophoresis of Treprostinil Induces a Sustained Increase in Cutaneous Blood Flux in Healthy Volunteers , 2013, Journal of clinical pharmacology.

[27]  D. Hirst,et al.  Nitric oxide physiology and pathology. , 2011, Methods in molecular biology.

[28]  N. Morrell,et al.  Smooth muscle proliferation and role of the prostacyclin (IP) receptor in idiopathic pulmonary arterial hypertension. , 2010, American journal of respiratory and critical care medicine.

[29]  John M. Johnson,et al.  Local thermal control of the human cutaneous circulation. , 2010, Journal of applied physiology.

[30]  M. Humbert,et al.  Systemic sclerosis-associated pulmonary arterial hypertension. , 2010, American journal of respiratory and critical care medicine.

[31]  P. Postmus,et al.  Nailfold capillary density is associated with the presence and severity of pulmonary arterial hypertension in systemic sclerosis , 2008, Annals of the rheumatic diseases.

[32]  M. Kramer,et al.  Peripheral endothelial dysfunction in patients with pulmonary arterial hypertension. , 2008, Respiratory medicine.

[33]  W. Seeger,et al.  Role of the prostanoid EP4 receptor in iloprost-mediated vasodilatation in pulmonary hypertension. , 2008, American journal of respiratory and critical care medicine.

[34]  Santiago Lorenzo,et al.  Human cutaneous reactive hyperaemia: role of BKCa channels and sensory nerves , 2007, The Journal of physiology.

[35]  N. Martinelli,et al.  Scleroderma patients nailfold videocapillaroscopic patterns are associated with disease subset and disease severity. , 2007, Rheumatology.

[36]  Jean-Luc Cracowski,et al.  Methodological issues in the assessment of skin microvascular endothelial function in humans. , 2006, Trends in pharmacological sciences.

[37]  Wiendelt Steenbergen,et al.  How to assess post-occlusive reactive hyperaemia by means of laser Doppler perfusion monitoring: application of a standardised protocol to patients with peripheral arterial obstructive disease. , 2005, Microvascular research.

[38]  Nisha Charkoudian,et al.  Skin blood flow in adult human thermoregulation: how it works, when it does not, and why. , 2003, Mayo Clinic proceedings.

[39]  T. Medsger,et al.  Predictors of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement. , 2003, Arthritis and rheumatism.

[40]  M. Nakane,et al.  A-350619: a novel activator of soluble guanylyl cyclase. , 2003, Life sciences.

[41]  M. Joyner,et al.  Nitric oxide and neurally mediated regulation of skin blood flow during local heating. , 2001, Journal of applied physiology.

[42]  D. Badesch,et al.  Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. , 1999, American journal of respiratory and critical care medicine.

[43]  B. Groves,et al.  An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. , 1992, The New England journal of medicine.

[44]  E. DeLong,et al.  Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. , 1988, Biometrics.

[45]  D. O'Leary,et al.  Effect of local warming on forearm reactive hyperaemia. , 1986, Clinical physiology.

[46]  W F Taylor,et al.  Effect of high local temperature on reflex cutaneous vasodilation. , 1984, Journal of applied physiology: respiratory, environmental and exercise physiology.

[47]  N Rowell,et al.  Systemic sclerosis. , 1968, British medical journal.